Is BioAdaptives Inc. (BDPT) a Buy, Sell, or Hold?
OTC : BDPT
BioAdaptives Inc.
$0.0023 USD
$0.0 (-19.16%)
- Volume
- 12.23M
- Average Volume
- 7.95M
- Market Capitalization
- $27.62K
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.07
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.05
Company Overview
OTC
James Keener
Packaged Foods
Consumer Defensive
BDPT
1
US
USD
Liquidity Metrics
-0.21
0.05
0.04
0.03
0.00
Sales & Valuation
$18278
1.16
-0.01
-0.05
-0.04
Profitability
-$0.15
-$1.56M
-6186.89%
-6186.89%
85.75%
-1082.75%
P/E Metrics
-0.02
0.00
0.00
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-162.44
3/9
-$2.15M
$135.95K
$2.27M
-$1.32M
Key Metrics (TTM)
$416.93K
17.52
-0.34
0.05
85.75%
58.92%
-4300.92%
-1522.16%
1343 days
Company Executives
| Name | Title |
|---|---|
| James Keener | Chief Executive Officer & Chairman |
Poll Results
No votes yet today — be the first to share your view!
About BioAdaptives Inc. (OTC:BDPT) Stock
BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals. It offers nutraceutical products, such as dietary supplements. The company offers Human Clinical trial; Zeranovia, a natural ingredient and uses proprietary methods of optimizing the availability of nutrients in foods and beverages; Lung Flute, a medical device; and Xcellara, PawPa, and MyndMed. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. The company was incorporated in 2013 and is based in Las Vegas, Nevada. ...
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
2026-08-03 08:00:00
Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced that the official opening of its commercial order window for XcellaraHeart™, the flagship product in the company's new Xcellara™ cellular wellness line, will take place later this week. Customers and distributors will soon be able to place orders directly through products.xcellara.com.
2026-07-30 08:30:00
Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, announced it has successfully retired its largest convertible commercial investor.
2026-07-29 13:15:00
LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront operations and direct-to-consumer (DTC) marketing footprint for its flagship cognitive performance line, MyndSystem™. The MyndSystem™ is a WADA-compliant, stimulant-free cognitive enhancement suite designed to support 24-hour brain performance.
2026-07-23 07:30:00
LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial manufacturing and logistics supply chain readiness. This milestone positions the company to roll out its next-generation wellness platforms beginning next month.
2026-07-16 08:30:00
Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas
2026-07-15 08:30:00
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular repair-response biology
2026-06-25 14:48:00
Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value consumer segments Certification validates the complete day-and-night neuro-performance and repair system, positioning the company for broader adoption across elite sports and high-value consumer segments
2026-05-20 16:15:00
Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during the day. Perform. Repair. Repeat. — A stimulant-free, dual-phase platform built on the principle that cognitive excellence depends as much on what the brain does overnight as on what it achieves during the day.
Frequently Asked Questions
-
What is the current BioAdaptives Inc. (BDPT) stock price?
-
BioAdaptives Inc.(OTC:BDPT) stock price is $0.0023 in the last trading session. During the trading session, BDPT stock reached the peak price of $0.07 while $0.0008 was the lowest point it dropped to. The percentage change in BDPT stock occurred in the recent session was --19.16% while the dollar amount for the price change in BDPT stock was -$0.0.
-
BDPT's industry and sector of operation?
-
The OTC listed BDPT is part of Packaged Foods industry that operates in the broader Consumer Defensive sector.
-
Who are the executives of BDPT?
-
James Keener | Chief Executive Officer & Chairman
|
|
|
| -
How many employees does BDPT have?
-
Number of BDPT employees currently stands at 1. BDPT operates from 2620 Regatta Drive, Las Vegas, NV 89128, US.
-
Link for BDPT official website?
-
Official Website of BDPT is: https://www.shopbioadaptives.com
-
How do I contact BDPT?
-
BDPT could be contacted at phone #702 659 8829 and can also be accessed through its website. BDPT operates from 2620 Regatta Drive, Las Vegas, NV 89128, US.
-
How many shares of BDPT are traded daily?
-
The average number of BDPT shares traded daily for last 3 months was 7.95M.
-
What is the market cap of BDPT currently?
-
The market value of BDPT currently stands at $27.62K with its latest stock price at $0.0023